Curis Lifesciences IPO Details
| Detail | Description |
|---|---|
| IPO Date | 7 th November 2025 - 11 th November 2025 |
| Listing Date | [.] |
| Face Value | ₹ 10 Per Share |
| Issue Price Band | ₹ 120 - ₹ 128 Per Share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 21,50,000 Shares (aggregating upto 27.52cr) |
| Reserved for Market Maker | 1,08,000 Shares (aggregating upto 1.3 cr) RS Wealth Management Private Ltd |
| Fresh Issue(Ex Market Maker) | 20,42,000 Shares (aggregating up to 26.14 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 59,34,434 Shares |
| Share Holding Post Issue | 80,84,434 Shares |
About Curis Lifesciences IPO
Curis Lifesciences Ltd is ready to launch its SME IPO on NSE Emerge from 7th November 2025 to 11th November 2025. It is a fresh issue of 0.22 crore shares worth ₹27.52 crore, with a price band of ₹120 to ₹128 per share. The face value per share is ₹10 per share. The tentative listing date of Curis Lifesciences IPO is 14th November 2025.
The lot size of the application is 1,000, with the minimum investment amount required by an individual investor (retail) at ₹2,56,000 (2,000 shares) based on the upper price and the minimum lot size investment is of 3 lots (3,000 shares), which is ₹3,84,000. Finaax Capital Advisors Pvt Ltd is the lead manager and MUFG Intime India Pvt Ltd is the registrar of the issue. RS Wealth Management Pvt Ltd is the Market Maker of this IPO.
Company Background
Curis Lifesciences Limited is a public limited company that was originally incorporated as Curis Lifesciences Private Limited in 2016 and was later converted into a public entity on 6th May 2024. This company is based in Ahmedabad, Gujarat and is involved in the manufacturing and marketing of medicines which include tablets, capsules, ointments, and creams.
The company focuses on maintaining high quality in its products and keeping them affordable for patients.
Operations And Product Range
Curis Lifesciences Ltd operates in advanced R&D and manufacturing facilities using modern biotechnology and pharmaceutical processes, which help create drug intermediates and research chemicals. It sells its products primarily through contracts with pharma companies and research centers.
Revenue Channels
Curis Lifesciences Ltd generates revenue by selling specialized drug ingredients to biotech and research institutions. It also provides custom products and research materials to the institutes. Apart from this, they export the products to international customers. The company reported revenue of ₹49.65 crore in FY 2025.
Management And Shareholding
The promoters of the Curis Lifesciences IPO include Dharmesh Dashrathbhai Patel, Siddhant Jayantibhai Pawasia, Piyush Gordhanbhai Antala, and Jaimik Mansukhbhai Patel. They hold the major share of the company’s equity, which reflects their deep involvement and long-term commitment to growth.
IPO Objectives of Curis Lifesciences IPO
The company proposes to utilize the IPO Net Proceeds towards the following objects:
- • Working capital requirements (₹2.44 crore) towards Upgradation/Improvement of the existing manufacturing facilities.
- • Capital expenditure requirements (₹3.62 crore) towards the construction of a storage facility.
- • Funding of the amount (₹11.25 crore) for the working capital requirements.
- • Prepayment or repayment of outstanding secured loans (₹1.86 crore).
- • The company proposes to utilize ₹2.69 crore for the registration of its products in other countries.
Conclusion
Curis Lifesciences IPO offers a lucrative opportunity for investors to invest in a reputed, growing pharmaceutical company that enjoys a strong presence in manufacturing a wide range of formulations like tablets, capsules, ointments, and syrups. Backed by a robust manufacturing base in Ahmedabad, the company is characterized by steady revenue and profit growth and is well-positioned to meet increasing healthcare demands in India and beyond.
The fresh capital raised through Curis Lifesciences IPO is expected to be used for upgrading manufacturing facilities, expanding storage capacity, supporting working capital needs, repaying debt, and funding international product registrations to strengthen operational capabilities and support future growth.
The IPO, priced between ₹120 and ₹128 per share, will list on NSE SME with a tentative listing date fixed as November 14, 2025. It has a book build issue of ₹27.52 crores, and the issue is entirely a fresh issue of 0.22 crore shares worth ₹27.52 crore.
Overall, the Curis Lifesciences IPO blends growth potential with focused deployment of funds and operational strength, making it an attractive consideration for investors seeking participation in the pharma space for the long term.
Curis Lifesciences IPO Financial Information
Latest Revenue
19.51
₹ Crore
Profit After Tax
2.87
₹ Crore
Net Worth
19.10
₹ Crore
Total Borrowing
15.32
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Total Borrowing | ||||
|---|---|---|---|---|---|---|---|---|---|
| 31 July 2025 | 56.29 | 19.51 | 2.87 | 19.10 | 15.32 | ||||
| 31 March 2025 | 42.53 | 49.65 | 6.11 | 16.23 | 15.62 | ||||
| 31 March 2024 | 33.88 | 35.87 | 4.87 | 5.87 | 17.09 | ||||
| 31 March 2023 | 29.75 | 36.42 | 1.88 | 1.01 | 16.19 | ||||
| Amount in ₹ Crore | |||||||||
Curis Lifesciences Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 55.25% |
| ROCE | 27.83% |
| Debt/Equity | 0.96 |
| RoNW | 37.62% |
| PAT Margin | 12.43% |
| EBITDA Margin | 19.41% |
| Price to Book Value | 12.64 |
| Market Capitalization | 103.48 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 10.29 | 10.66 |
| P/E (x) | 12.44 | 12.01 |
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Curis Lifesciences manufactures a wide range of pharmaceutical formulations which include tablets, capsules, syrups and ointments for multiple segments.
It has a strong manufacturing base in Ahmedabad and is growing domestically.
For the past few years, it has shown steady growth in revenue and profitability with an increase in demand for healthcare products and manufacturing services.
Download regulatory filings
Curis Lifesciences IPO Timeline
| IPO Open Date | 7th November 2025 |
| IPO Close Date | 11th November 2025 |
| Tentative Allotment | 12th November 2025 |
| Initiation of Refunds | 13th November 2025 |
| Credit of Shares to Demat | 13th November 2025 |
| Tentative Listing Date | 14th November 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on 11th November 2025 |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,56,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,56,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,84,000 |
| S-HNI (Max) | 7 | 7,000 | ₹8,96,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,24,000 |